He, X., Yu, J., & Shi, H. (2021). Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Frontiers Media S.A.
Cita Chicago Style (17a ed.)He, Xiujing, Jing Yu, y Hubing Shi. Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Frontiers Media S.A, 2021.
Cita MLA (8a ed.)He, Xiujing, et al. Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Frontiers Media S.A, 2021.
Precaución: Estas citas no son 100% exactas.